Akebia Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio
Akebia Therapeutics (Cambridge, MA): 1 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend, and $2,556 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Cambridge, MA |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2036-01-01 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| California HCAI SB 17 Filings | Specialty launch notice ($2,556 intro WAC) |